Eikon Therapeutics

Biotech startup developing innovative medicines

Hayward, California, United States

About Eikon Therapeutics

Eikon Therapeutics focuses on discovering and developing new medicines in the pharmaceutical industry. The company employs advanced technologies to study biological systems, aiming to identify new drug targets by examining the dynamic aspects of biology rather than just static chemical processes. Their team consists of diverse professionals, including data scientists, chemists, and engineers, which allows them to combine science and engineering to create new therapies that aim to improve and extend life. A key feature of Eikon's approach is their proprietary single-molecule tracking (SMT) platform, which enables rapid visualization of protein movements in living cells. This technology, along with artificial intelligence and automation, allows for precise inventorying of molecular interactions. Eikon Therapeutics targets patients with serious diseases who need effective treatments, generating revenue through the development and commercialization of their therapies.

Hayward, CaliforniaHeadquarters
2019Year Founded
$750.8MTotal Funding
SERIES_CCompany Stage
AI & Machine Learning, BiotechnologyIndustries
201-500Employees

Benefits

401(k) Company Match
Medical (premiums covered by Eikon at 95%)
Dental Insurance
Vision Insurance
Mental Health Support
Unlimited Paid Time Off
Paid Holidays
Life Insurance
Enhanced Parental Leave
Daily subsidized lunch program

Risks

Competition from biotech unicorns like Abogen Biosciences is increasing.
Integrating new clinical-stage assets may delay drug development timelines.
Reliance on SMT technology risks obsolescence from emerging molecular biology technologies.

Differentiation

Eikon uses proprietary single-molecule tracking for real-time protein movement analysis.
The company integrates AI and automation for large-scale molecular interaction studies.
Eikon's diverse team combines expertise in science, engineering, and technology.

Upsides

Growing interest in SMT technology boosts Eikon's drug discovery potential.
Partnerships with AI firms enhance Eikon's drug candidate identification.
Rising demand for precision medicine aligns with Eikon's focus on dynamic biology.